Key result
Propylthiouracil therapy for 30 days in newly diagnosed Basedow patients significantly decreased nitric oxide and TBARS and increased GSH and CuZn SOD levels compared to pre-treatment baseline.
Why the study?
Does propylthiouracil treatment improve oxidative stress and nitric oxide levels in newly diagnosed Basedow disease patients?
Observational (n=42)
Does propylthiouracil treatment improve oxidative stress and nitric oxide levels in newly diagnosed Basedow disease patients?
Propylthiouracil therapy in Basedow disease patients improves antioxidant defense and decreases nitric oxide levels, highlighting its role in reducing oxidant generation.
Answers are grounded in this paper and cite their sources.
May indicate antioxidant benefit of propylthiouracil in Basedow disease; hypothesis-generating and should not change practice.
Oxidative stress parameters and nitric oxide (NO) values were determined in 27 newly diagnosed Basedow patients before and after 1 mo of propylthiouracil (PTU) therapy and in 15 healthy controls. Basedow patients exhibited increased triiodothyronine (T3) and thyroxine (T4) and decreased thyroid-stimulating hormone (TSH) values compared to controls. Significantly higher thiobarbituric acid-reactive substances (TBARS), NO and glutathione (GSH) levels, and CuZn superoxide dismutase (CuZn SOD) activity were found in Basedow patients in comparison to controls, regardless of sex. Treatment with PTU (3 x 100 mg/d for 30 d) was effective in decreasing T1 and T4 and increasing TSH levels. Significantly decreased NO and TBARS and increased GSH and CuZn SOD levels were observed in PTU-treated Basedow patients compared to pre-PTU administration. PTU-treated patients compared to controls still exhibited significantly higher T3 and lower TSH values and higher NO, TBARS, GSH, and CuZn SOD levels. The induced antioxidant defense and decrease in NO) values in response to PTU therapy emphasizes the role of PTU as an antithyroid drug, where the ability to diminish hyperthyroidism results in decreased catabolism and lower oxidant generation.
No takes yet. Share an insight, caveat, or question.
Seven et al. (2001) conducted an observational in Basedow disease (n=42). Propylthiouracil (PTU) vs. Pre-PTU administration and healthy controls was evaluated on Oxidative stress parameters (TBARS, GSH, CuZn SOD) and nitric oxide (NO) values. Propylthiouracil therapy for 30 days in newly diagnosed Basedow patients significantly decreased nitric oxide and TBARS and increased GSH and CuZn SOD levels compared to pre-treatment baseline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: